We are looking for an Early Commercial Lead to shape the commercial strategy for Ontunisertib, a GI-restricted small molecule ALK5 inhibitor currently ready for Phase 2b development in Fibrostenosing Crohn’s Disease (FSCD). FSCD represents a significant unmet need within the Crohn’s disease population, with limited therapeutic options addressing the intestinal fibrosis and stricturing complications. Ontunisertib is the most advanced clinical candidate for the potential treatment of FSCD. The role will play a pivotal part in defining the future value proposition, positioning, and evidence strategy for Ontunisertib as it progresses through clinical development. As the commercial lead for Ontunisertib, you will work closely with clinical development, regulatory and corporate functions to ensure that future development plans align with the market. The role sits at the intersection of science, clinical strategy, corporate and commercial planning, helping translate emerging clinical insights into a compelling strategy that ultimately improves outcomes for patients with FSCD. The role will report to the Chief Business Officer. Key Responsibilities What will you do? Asset Strategy & Early Commercial Planning: Lead development of the global early commercial and market access strategy Shape the Target Product Profile (TPP) based on emerging clinical and economic data Define patient segmentation and treatment positioning within the Crohn’s disease paradigm Translate scientific and clinical data into integrated value propositions Market Access Strategy: Develop the early global market access strategy Identify key access drivers and barriers across major markets Support development of early health economic models and value hypotheses Provide input into pricing scenarios and access assumptions to inform development decisions Anticipate future HTA requirements and payer evidence expectations Disease Area Strategy: Build deep insights into the FSCD landscape, including epidemiology, clinical burden, patient journey, and treatment gaps Support development of the disease area strategy, highlighting the unmet need in FSCD Partner with internal teams to raise awareness for FSCD Evidence & Value Generation: Collaborate with Clinical Development to shape the evidence generation roadmap Identify key data gaps required for physician adoption, guideline inclusion, payer value demonstration and reimbursement Contribute to development of the scientific narrative and future value dossiers Stakeholder Insights & KOL Engagement: Develop strong insights from gastroenterologists, FSCD experts and payers and HTA bodies Support advisory boards, market and payer research, and KOL engagement initiatives Translate external insights into actionable recommendations for asset development Competitive & Market Intelligence Monitor the evolving IBD and fibrosis competitive landscape Cross-Functional Leadership Serve as the commercial representative within the cross-functional asset team to ensure alignment between clinical development and regulatory plans and future commercial needs Serve as commercial sparring partner for other programs in the Agomab pipeline Skills, Knowledge and Expertise Who are you? Master’s degree in life sciences, pharmacy, medicine, or business. An MBA or PhD is a plus Experience in a comparable global marketing, market access, (asset) strategy or medical affairs role Strong understanding of inflammatory bowel disease. Knowledge of Fibrosis markets is a plus Demonstrated experience working in cross-functional asset teams Benefits What we offer The opportunity to develop pioneering science in a young biotech company Challenging and innovative work environment as part of a driven team Flexibility and responsibility based in Antwerp, with remote working options that can be tailored for you Competitive salary and benefits An agile and fast paced environment